Verastem: new chairman, president of development appointed; COO departs; RAMP 301 enrollment complete

Verastem, Inc.

John Johnson appointed chairman of board; Michael Kauffman, MD, PhD, becomes president of development, leaving lead director role.
Matthew Ros, COO, departs; receives nine-month base salary continuation and pro-rated bonus under separation agreement.
RAMP 301 Phase 3 trial in recurrent LGSOC completed additional enrollment of 29 patients; topline data expected mid-2027.
Commercial launch of AVMAPKI FAKZYNJA CO-PACK progressing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.